세계의 센트럴 랩 서비스/임상시험 실험실 서비스 시장 : 상별, 서비스 유형별, 치료 분야별, 모달리티별, 최종사용자별, 지역별 - 예측(-2030년)

The global Central lab services/clinical trial lab services market is projected to reach USD 8.18 billion by 2030 from USD 5.97 billion in 2025, at a CAGR of 6.5% during the forecast period.

This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030.

"The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period."

Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market.

"The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market."

Based on theraprutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market.

"Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region."

The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for entral lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country's growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%
• By Designation: C-level-25%, Director-level-30% and Others-45%
• By Region: North America-40%, Europe-25%, Asia Pacific-20%, Latin America- 10%, and Middle east and Africa - 5%

Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the central lab services/clinical trial lab services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Societe Generale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), and REPROCELL Inc. (Japan).

Research Coverage

This report studies the central lab services/clinical trial lab services market based on product, type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

• Analysis of Key divers (Increasing number of clinical trials, increasing investments in research & development, growing prevalence of rare diseases), restraints (High cost associated with clinicaltrials, Shortage of skilled professionals), opportunity (Emerging markets worldwide, decentralized and virtual clinical trials), Challenge (regulatory complexities, limited patient diversity and cybersecurity or intellectual property concerns)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the central lab services/clinical trial lab services market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the central lab services/clinical trial lab services market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.2.1.3 Approach 3: Primary interviews
    • 2.2.1.4 Growth forecast
    • 2.2.1.5 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
  • 2.4.1 STUDY-RELATED ASSUMPTIONS
  • 2.4.2 PARAMETRIC ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET OVERVIEW
• 4.2 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER AND COUNTRY
• 4.3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY
• 4.4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, REGIONAL MIX, 2025 VS. 2030

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing number of clinical trials
    • 5.2.1.2 Rising investments in research & development
    • 5.2.1.3 Growing prevalence of rare diseases
    • 5.2.1.4 Favorable government initiatives
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs associated with clinical trials
    • 5.2.2.2 Shortage of skilled professionals
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emerging markets worldwide
    • 5.2.3.2 Decentralized and virtual clinical trials
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory complexities
    • 5.2.4.2 Limited patient diversity
    • 5.2.4.3 Cybersecurity and intellectual property concerns
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 RESOURCE ACQUISITION AND PREPARATION
  • 5.4.2 CLINICAL TRIAL EXECUTION
  • 5.4.3 DATA REPORTING AND RESULT SUBMISSION
  • 5.4.4 PROMOTION AND REGULATORY FILING
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 INVESTMENT AND FUNDING SCENARIO
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Enzyme-linked immunosorbent assay
  • 5.7.2 ADJACENT TECHNOLOGIES
    • 5.7.2.1 Next-generation sequencing
• 5.8 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.9 CASE STUDY ANALYSIS
  • 5.9.1 PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH)
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY FRAMEWORK
    • 5.10.1.1 North America
    • 5.10.1.2 Europe
    • 5.10.1.3 Asia Pacific
    • 5.10.1.4 Rest of the World
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
  • 5.13.1 INTRODUCTION
  • 5.13.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES
  • 5.13.3 AI USE CASES
  • 5.13.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM

6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE

• 6.1 INTRODUCTION
• 6.2 PHASE I
  • 6.2.1 NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH
• 6.3 PHASE II
  • 6.3.1 NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET
• 6.4 PHASE III
  • 6.4.1 RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET
• 6.5 PHASE IV
  • 6.5.1 ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH

7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE

• 7.1 INTRODUCTION
• 7.2 SAFETY TESTING
  • 7.2.1 NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH
• 7.3 IMMUNOLOGY
  • 7.3.1 INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH
• 7.4 GENETIC TESTING
  • 7.4.1 GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET
• 7.5 COAGULATION TESTING
  • 7.5.1 ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH
• 7.6 PATHOLOGY TESTING
  • 7.6.1 ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH
• 7.7 BIOMARKERS
  • 7.7.1 NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH
• 7.8 COMPANION DIAGNOSTICS
  • 7.8.1 GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET
• 7.9 OTHER TESTS

8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA

• 8.1 INTRODUCTION
• 8.2 ONCOLOGY
  • 8.2.1 INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH
• 8.3 INFECTIOUS DISEASES
  • 8.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH
• 8.4 NEUROLOGY
  • 8.4.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH
• 8.5 CARDIOLOGY
  • 8.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET
• 8.6 OTHER THERAPEUTIC AREAS

9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY

• 9.1 INTRODUCTION
• 9.2 SMALL MOLECULES
  • 9.2.1 EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH
• 9.3 BIOLOGICS
  • 9.3.1 MONOCLONAL ANTIBODIES
    • 9.3.1.1 Growing advancements in antibody engineering to drive market
  • 9.3.2 VACCINES
    • 9.3.2.1 Increasing investments in vaccine development to favor growth
  • 9.3.3 OTHER THERAPEUTIC PRODUCTS
• 9.4 CELL & GENE THERAPY
  • 9.4.1 OUTSOURCING TREND TO FAVOR GROWTH
• 9.5 MEDICAL DEVICES & IVD DEVICES
  • 9.5.1 RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET

10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 10.2.1 EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH
• 10.3 CLINICAL RESEARCH ORGANIZATIONS
  • 10.3.1 CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET
• 10.4 MEDICAL DEVICE COMPANIES
  • 10.4.1 RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH
• 10.5 OTHER END USERS

11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Increasing clinical trials to support growth
  • 11.2.3 CANADA
    • 11.2.3.1 Rising incidence of chronic diseases to advance growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Increasing healthcare expenditure to intensify growth
  • 11.3.3 FRANCE
    • 11.3.3.1 Growing investments in life sciences sector to boost market
  • 11.3.4 UK
    • 11.3.4.1 High number of oncology clinical trials to facilitate growth
  • 11.3.5 ITALY
    • 11.3.5.1 Rising focus on streamlining clinical trial process to expedite growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Emerging biotech companies to bolster growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Growing demand for drug development to propel market
  • 11.4.3 CHINA
    • 11.4.3.1 Booming pharmaceutical industry to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing regulatory reforms to foster growth
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH
  • 11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET
  • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Product type footprint
    • 12.7.5.4 Therapeutic area footprint
    • 12.7.5.5 Phase footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 IQVIA
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 ICON PLC
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 CHARLES RIVER LABORATORIES
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
      • 13.1.4.3.2 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 LABCORP
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Expansions
      • 13.1.5.3.4 Other developments
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 QUEST DIAGNOSTICS
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
  • 13.1.7 MEDPACE
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Expansions
  • 13.1.8 FRONTAGE LABS
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
  • 13.1.9 SGS SOCIETE GENERALE DE SURVEILLANCE SA
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Deals
  • 13.1.10 EUROFINS SCIENTIFIC
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 REPROCELL INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Deals
  • 13.1.12 ACM GLOBAL LABORATORIES
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 WORLDWIDE CLINICAL TRIALS
  • 13.2.2 VERSITI
  • 13.2.3 CTI CLINICAL TRIAL & CONSULTING
  • 13.2.4 CLARITY LABORATORIES, INC
  • 13.2.5 NOVOTECH
  • 13.2.6 ARUP LABORATORIES
  • 13.2.7 PRECISION MEDICINE GROUP
  • 13.2.8 BIOAGILYTIX LABS
  • 13.2.9 CERBA HEALTHCARE
  • 13.2.10 ALMAC GROUP
  • 13.2.11 MLM MEDICAL LABS
  • 13.2.12 SALVUS BIORESEARCH SOLUTIONS LLP
  • 13.2.13 UNILABS

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS